Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Valerie Morisset Sells 69,005 Shares

Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Valerie Morisset sold 69,005 shares of the business’s stock in a transaction that occurred on Monday, July 22nd. The stock was sold at an average price of $8.03, for a total value of $554,110.15. Following the sale, the executive vice president now directly owns 31,317 shares in the company, valued at $251,475.51. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Valerie Morisset also recently made the following trade(s):

• On Friday, July 19th, Valerie Morisset sold 60,201 shares of Eliem Therapeutics stock. The stock was sold at an average price of $7.21, for a total value of $434,049.21.
• On Wednesday, July 17th, Valerie Morisset sold 3,207 shares of Eliem Therapeutics stock. The stock was sold at an average price of $6.91, for a total value of $22,160.37.
• On Monday, July 15th, Valerie Morisset sold 42,377 shares of Eliem Therapeutics stock. The stock was sold at an average price of $7.01, for a total value of $297,062.77.
• On Thursday, July 11th, Valerie Morisset sold 50,000 shares of Eliem Therapeutics stock. The stock was sold at an average price of $7.11, for a total value of $355,500.00.
• On Tuesday, July 9th, Valerie Morisset sold 5,931 shares of Eliem Therapeutics stock. The stock was sold at an average price of $6.66, for a total value of $39,500.46.
• On Friday, July 5th, Valerie Morisset sold 12,342 shares of Eliem Therapeutics stock. The stock was sold at an average price of $7.06, for a total value of $87,134.52.
• On Wednesday, July 3rd, Valerie Morisset sold 50,000 shares of Eliem Therapeutics stock. The stock was sold at an average price of $6.76, for a total value of $338,000.00.

Eliem Therapeutics Price Performance

NASDAQ ELYM traded up $0.61 during midday trading on Tuesday, hitting $8.93. 292,593 shares of the company traded hands, compared to its average volume of 458,660. The company has a market cap of $265.67 million, a PE ratio of -16.53 and a beta of -0.33. The company’s 50-day simple moving average is $7.66 and its 200-day simple moving average is $5.03. Eliem Therapeutics, Inc. has a 52 week low of $2.35 and a 52 week high of $11.55.

Eliem Therapeutics (NASDAQ:ELYM) last announced its earnings results on Wednesday, May 15th. The company reported ($0.06) earnings per share (EPS) for the quarter.

Institutional Trading of Eliem Therapeutics

A hedge fund recently raised its stake in Eliem Therapeutics stock. BML Capital Management LLC lifted its holdings in Eliem Therapeutics, Inc. (NASDAQ:ELYM) by 12.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,180,000 shares of the company’s stock after purchasing an additional 241,737 shares during the quarter. Eliem Therapeutics comprises about 4.4% of BML Capital Management LLC’s portfolio, making the stock its 6th biggest position. BML Capital Management LLC owned approximately 7.91% of Eliem Therapeutics worth $5,886,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 69.76% of the company’s stock.

About Eliem Therapeutics

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.